Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
IBTROZI's Triumph | Nuvation Bio's transition to a commercial-stage company with FDA approval of IBTROZI for ROS1-positive NSCLC marks a pivotal moment in oncology treatment |
Market Dynamics | Explore IBTROZI's competitive edge in ROS1+ NSCLC treatment, its pricing strategy, and its potential to reshape the market landscape |
Financial Fortitude | Delve into Nuvation Bio's robust financial position, with analyst price targets ranging from $5 to $10 per share and projected peak sales of $2.5 billion globally |
Future Horizons | Uncover Nuvation Bio's promising pipeline, including safusidenib and NUV-1511, poised to expand the company's oncology portfolio and market presence |
Metrics to compare | NUVB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVBPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.0x | 22.3x | −0.5x | |
PEG Ratio | −0.07 | 0.54 | 0.00 | |
Price/Book | 2.7x | 5.5x | 2.6x | |
Price / LTM Sales | 70.8x | 1.8x | 3.3x | |
Upside (Analyst Target) | 118.9% | 277.8% | 38.9% | |
Fair Value Upside | Unlock | 16.1% | 5.4% | Unlock |